High-grade B-cell Lymphoma Clinical Trial
Official title:
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
Status | Recruiting |
Enrollment | 40 |
Est. completion date | November 2028 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | Inclusion Criteria: - Histologically confirmed, R/R, B-cell NHL according to the 2022 revision of the World Health Organization classification of lymphoid neoplasms [Alaggio 2022] defined as any of the following: 1. LBCL 2. FL Grade 3b 3. MCL - The following criteria apply for details of prior treatment/therapy: R/R to at least 2 lines of therapy; if the most recent line of therapy was autologous hematologic cell transplant (HCT), relapse within 12 months of the transplant. - Measurable disease by scan (diagnostic positron emission tomography-positive and/or computed tomography-measurable) as per Lugano Classification [Cheson 2014]. Magnetic resonance imaging may be used when computed tomography with contrast is contraindicated or when mandated by local practice. - If sufficient archival material is not available from the latest relapse, a new tumor biopsy is required any time during screening, prior to conditioning chemotherapy. - Participants with LBCL who have received prior CD19-directed therapy as the prior line of therapy: 1. must have achieved either a CR or partial response as a best response and maintained the response for = 3 months after receiving CD19-directed treatment, and 2. must still have CD19+ disease as determined by a local laboratory. - Eastern Cooperative Oncology Group performance status = 1 - Adequate organ function - Written informed consent as per protocol. - Participants are able to commit to the inpatient portion of the study, encompassing conditioning (if per the institution's standard practice), and frequent monitoring during Days 1-15, as well as remain within 1 hour travel time of the clinical site for 28 days after each infusion. Exclusion Criteria: - History of a human immunodeficiency virus infection or acute or chronic active hepatitis B or C infection. - History or presence of clinically relevant central nervous system pathology. - Unresolved Grade 1-2 Immune effector cell-associated neurotoxicity syndrome (ICANS) or experienced Grade 3-4 ICANS from prior chimeric antigen receptor T-cell. - Unresolved graft-versus-host disease (GvHD) or Grade 3-4 acute GvHD from any prior therapy or moderate to severe chronic GvHD from any prior therapy. - History of any one of the following cardiovascular conditions: class III or IV heart failure as defined by the New York Heart Association [The Criteria Committee of the New York Heart Association 1994], cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically meaningful cardiac disease, within the past 6 months of study informed consent. - History of malignancies, other than R/R NHL, unless the participant has been disease-free for = 2 years (certain noninvasive malignancies are allowed). - Active primary/CNS-only involvement by lymphoma, unless the CNS involvement has been effectively treated. - Active autoimmune disorders or inflammatory conditions that require systemic immunosuppressive therapies, including therapeutic doses of steroids. - Has received prior allogeneic HCT or prior solid organ transplant. - Systemic bacterial, viral, fungal, or other infection that is untreated or unresponsive to appropriate treatment (or requires IV antibiotics at enrollment); participants must be afebrile for = 48 hours. Prophylactic antibiotics, antivirals, and antifungals are permitted. - Concurrent serious uncontrolled or unresolved medical condition, including any laboratory abnormality or psychiatric illness. - For participants with MCL or FL, any prior CD19-directed therapy. - The following therapies within defined periods prior to the conditioning regimen: therapeutic doses of corticosteroids (> 0.5 mg/kg/day of prednisone or equivalent), lymphodepleting chemotherapeutic agents, live attenuated vaccines, prior systemic cancer therapy, investigational agents, including approved drugs being used off label, autologous HCT, donor lymphocyte infusions, radiation, alemtuzumab. - Female who is breastfeeding or pregnant. - Inability or unwillingness to comply with study procedures. - Unwilling to use protocol specified contraceptive methods |
Country | Name | City | State |
---|---|---|---|
United States | Norton Cancer Institute | Louisville | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Atara Biotherapeutics |
United States,
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferr — View Citation
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) | Day 1 through 90 days after the last dose of study drug | ||
Primary | Incidence and Severity of Adverse Events of Special Interest (AESIs) | Day 1 through 90 days after the last dose of study drug | ||
Primary | Clinically Significant Changes in Laboratory Parameters | Day 1 through 90 days after the last dose of study drug | ||
Primary | Incidence of Dose-limiting Toxicities (DLTs) | Day 1 through Day 28 of first dose | ||
Primary | Maximum Tolerated dose (MTD) | Day 1 through Day 28 of first dose | ||
Primary | Recommended Phase 2 Dose (RP2D) | Day 1 through Day 28 of first dose | ||
Secondary | Maximum Observed Plasma Concentration (Cmax) of ATA3219 | Pre-dose Day 1 through 24 months after last dose on a defined schedule | ||
Secondary | Time to Reach Cmax of ATA3219 | Pre-dose Day 1 through 24 months after last dose on a defined schedule | ||
Secondary | Partial Area Under the Curve (pAUC) of ATA3219 | Pre-dose Day 1 through 24 months after last dose on a defined schedule | ||
Secondary | Last Observed Plasma Concentration (Clast) of ATA3219 | Pre-dose Day 1 through 24 months after last dose on a defined schedule | ||
Secondary | Time of Clast of ATA3219 | Pre-dose Day 1 through 24 months after last dose on a defined schedule | ||
Secondary | Terminal Half-life (T1/2) of ATA3219 | Pre-dose Day 1 through 24 months after last dose on a defined schedule | ||
Secondary | Objective Response Rate (ORR) | Screening (= 28 days before enrollment) through 24 months after last dose | ||
Secondary | Complete Response Rate (CRR) | Screening (= 28 days before enrollment) through 24 months after last dose | ||
Secondary | Time-to-response (TTR) | Screening (= 28 days before enrollment) through 24 months after last dose | ||
Secondary | Duration of Response (DOR) | Screening (= 28 days before enrollment) through 24 months after last dose | ||
Secondary | Progression-free Survival (PFS) | Screening (= 28 days before enrollment) through 24 months after last dose | ||
Secondary | Overall Survival (OS) | Screening (= 28 days before enrollment) through 24 months after last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04555811 -
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
|
Phase 1 | |
Recruiting |
NCT04226937 -
DLBCL Interim Response Evaluation for Customised Therapy
|
||
Not yet recruiting |
NCT05834426 -
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
|
||
Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT06093841 -
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL
|
Phase 2 | |
Recruiting |
NCT04300998 -
Study of CAR-T Therapy in Older Patients
|
||
Recruiting |
NCT04796857 -
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
|
Phase 1/Phase 2 | |
Completed |
NCT04933617 -
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
|
Phase 1 | |
Terminated |
NCT04358458 -
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT05621096 -
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT06287398 -
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
|
Phase 2 | |
Recruiting |
NCT04836507 -
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT04594642 -
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
Terminated |
NCT04844086 -
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT04858568 -
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
|
||
Recruiting |
NCT04855253 -
Study of E7777 Prior to Kymriah for R/R DLBCL
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04914741 -
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06343311 -
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04067414 -
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
|
Phase 1 | |
Terminated |
NCT03132584 -
Cyclophosphamide and Alemtuzumab In Lymphoma
|
Phase 1 |